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Conclusion: The historically found dosimetric advantages for 
prone setup will persist if modern dose delivery techniques 
are used, combined with large margins. However, the 
advantage is lost for small margins and if prone setup needs a 
larger margin than supine setup. 
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Purpose or Objective: The mutual movement of the tumour 
and treatment delivery during VMAT might cause hotspots 
and coldspots in the dose distribution, so-called interplay 
effects. These can be hard to predict and might be of great 
concern for hypo-fractionated VMAT treatments. The purpose 
of this study was (1) to develop a method to calculate the 
absorbed dose to moving tumours for VMAT treatments, (2) 
verify the proposed method by measurements, and (3) use 
the proposed method to investigate the dosimetric impact of 
interplay effects for hypo-fractionated FFF VMAT treatment 
of moving liver tumours. 
 
Material and Methods: Treatment plans using 6 MV FFF VMAT 
(1400 MU/min) were created for three liver metastases 
(TrueBeam and Eclipse, Varian Medical Systems). The 
prescribed dose was 36 Gy in 3 fractions. The arcs were 
divided into sub-beams (one for every two control points) 
using an in-house developed software and the isocenter was 
shifted for every sub-beam to simulate sinusoidal motion in 
the superior-inferior direction. The sub-beams were 
calculated in Eclipse, generating a 4D dose distribution 
including effects of motion. For each treatment plan, 
combinations of three different motion amplitudes (5, 15 and 
25 mm peak-to-peak) and periods (3, 5 and 7 s) were 
simulated. To separate the interplay effect from dose 
blurring, the original 3D dose distribution was convolved with 
the motion pattern and subtracted from the simulated 4D 
dose distribution, and the resulting D1%-D99% was calculated 
for the ITV. To verify the method, simulated treatment plans 
were delivered in developer mode to the Delta4 phantom 
positioned on Hexamotion (ScandiDos), which was either 
static or moving sinusoidally with a peak-to-peak distance of 
15 mm and a period time of 5 seconds during irradiation. The 
measured and simulated dose distributions were compared 
using gamma analysis (2%/2 mm local dose, cut-off dose 10%) 
in the Delta4 software. To synchronize the isocenter shifts in 
the simulations with the motion during the measurements, kV 
images were acquired asynchronously during beam delivery. 
 
Results: Gamma analysis show good agreement between the 
simulated 4D dose distribution and the dynamic 
measurement, comparable to the original 3D dose 
distribution and the static measurement (table 1). The 
impact of the interplay effects, expressed as D1%-D99%, 
varies considerably between targets as well as the 
combination of tumour amplitude and period time (figure 1), 
with a maximum difference in D1%-D99% compared to no 
motion of 2.8 Gy (target 2, 25 mm, 7s). 
 
 
 
Conclusion: A method to calculate the absorbed dose to 
moving tumours was developed and verified by 
measurements. Using this method, it was shown that large 
interplay effects may occur, with no obvious relation to the 
motion pattern. Therefore, caution should be taken before 
using FFF VMAT for moving liver tumours without using 
motion management techniques. 
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Purpose or Objective: In order to assess treatment plan 
quality a good strategy is to compare plan quality indices for 
similar patients treated previously. For SBRT treatments the 
dose gradient is strongly associated with plan quality. Our 
objective is to introduce and show the merits of a gradient 
index for (lung) SBRT treatment plans that is, in contrast with 
existing indices, usable for multiple tumors and is readily 
interpretable. 
 
Material and Methods: Our gradient index is defined as the 
relative dose-gradient averaged over the voxels in the first 
centimeter around the PTV. When a patient has multiple 
tumors, voxels closer to other tumors are excluded from the 
average, see inset of Fig. 1. For 100 tumors of lung SBRT 
patients treated in our clinic we calculated the proposed 
gradient index as well as other possible quality indices, such 
as conformity (ratio of volume receiving prescribed dose to 
volume of PTV) and inhomogeneity (ratio of max and 
prescribed dose). In addition, we listed geometric parameters 
such as volume, position in the lung, and distance to various 
OARs of the GTVs. We establish the mutual correlations of 
the plan quality indicators and dependencies on geometric 
factors. To test whether the suggested parameter indeed 
measures quality we select five low-scoring patients, 
including a patient with multiple tumors, and try to improve 
the treatment plans with respect to the suggested gradient 
index without compromising other constraints. 
 
Results: For peripheral tumors the average relative dose-
gradient in the first cm from the edge of the PTV is 5.6 ± 0.6 
%/mm, shown in Fig. 1. It is independent of volume, position 
in the lung and does not correlate with the conformity index, 
in contrast to other gradient indices. For five low-scoring 
patients we could improve the dose-gradient on average by 
0.5 %/mm without compromising target coverage and 
conformity. By increasing the gradient in the first centimeter 
around the PTV the average dose in most OARs was reduced, 
with an 8% reduction in average dose to the whole patient 
excluding PTV and an 6% reduction to average dose to 
healthy lung tissue. 
 
